AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
Status:
RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).